Replies to post #222786 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Essentially, yes.

Hey Flip, haven't you been saying this, with respect to crossover -- Survivor

"While the administration of DCVs after maximal surgical resection is typically advocated due to the idea that decreased tumor burden leads to a decrease in tumor-associated immune suppression and stronger cytotoxic immune response, the timing of DCVs in conjunction with or after adjuvant chemoradiation is less clear [218]" -- https://www.mdpi.com/2072-6694/11/4/537/htm